VERV Stock Overview
A clinical-stage company, develops gene editing medicines for patients to treat cardiovascular disease in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
Verve Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.76 |
| 52 Week High | US$9.31 |
| 52 Week Low | US$2.86 |
| Beta | 1.87 |
| 1 Month Change | 10.34% |
| 3 Month Change | -20.55% |
| 1 Year Change | -7.99% |
| 3 Year Change | -62.89% |
| 5 Year Change | n/a |
| Change since IPO | -81.95% |
Recent News & Updates
Verve Therapeutics: FDA Fast Track And Eli Lilly Partnership Upgrade It To A 'Buy'
Apr 16Verve Therapeutics: HeFH Treatment Program Of VERVE-102 Remains On Track With 2025 Catalysts
Mar 25Recent updates
Verve Therapeutics: FDA Fast Track And Eli Lilly Partnership Upgrade It To A 'Buy'
Apr 16Verve Therapeutics: HeFH Treatment Program Of VERVE-102 Remains On Track With 2025 Catalysts
Mar 25Verve Therapeutics: Key Data Catalysts, Major Share Price Volatility In Play In Q2
Feb 28Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth
Dec 08
Verve Therapeutics: An In Vivo Gene Editing 'Moon Shot' For Your Portfolio
Aug 30Earnings Release: Here's Why Analysts Cut Their Verve Therapeutics, Inc. (NASDAQ:VERV) Price Target To US$25.78
Aug 10We're Not Very Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Rate
Jul 12Why Verve Therapeutics Deserves A Spot On Your Watchlist
Jun 13Broker Revenue Forecasts For Verve Therapeutics, Inc. (NASDAQ:VERV) Are Surging Higher
May 14The Verve Therapeutics, Inc. (NASDAQ:VERV) First-Quarter Results Are Out And Analysts Have Published New Forecasts
May 12Verve Therapeutics Stock Remains A Hold After VERVE-101 Enrollment Pause
Apr 03Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth
Feb 28Verve's Proof-Of-Concept Data Doesn't Inspire Confidence
Feb 13Vectoring In On Verve Therapeutics
Jan 14Here's Why We're Not Too Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Situation
Jun 07Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth
Feb 24We Think Verve Therapeutics (NASDAQ:VERV) Can Afford To Drive Business Growth
Nov 09Verve Therapeutics: Cathie Wood Adds To ARKK
Sep 20Why did Verve Therapeutics stock jump today? Data on high cholesterol candidate
Aug 23Verve Therapeutics falls postmarket on $200M stock offering
Jul 20More CRISPR In Human Subjects
Jul 14Here's Why We're Not Too Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Situation
May 11Verve Therapeutics: Early-Stage Biotech With A Large Market
Apr 16Verve Therapeutics (NASDAQ:VERV) Is In A Good Position To Deliver On Growth Plans
Jan 31Shareholder Returns
| VERV | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 20.5% | 4.4% | 7.0% |
| 1Y | -8.0% | -5.0% | 7.5% |
Return vs Industry: VERV underperformed the US Biotechs industry which returned -5% over the past year.
Return vs Market: VERV underperformed the US Market which returned 7.5% over the past year.
Price Volatility
| VERV volatility | |
|---|---|
| VERV Average Weekly Movement | 16.4% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 7.8% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: VERV's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: VERV's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 274 | Sek Kathiresan | www.vervetx.com |
Verve Therapeutics, Inc., a clinical-stage company, develops gene editing medicines for patients to treat cardiovascular disease in the United States. The company’s product candidates include VERVE-101, which is being evaluated in the Heart-1 trial, an open-label Phase 1b clinical trial, as well as changes in blood PCSK9 protein and LDL-C levels in patients living with heterozygous familial hypercholesterolemia (HeFH); VERVE-102 that is being evaluated in the Heart-2 trial, an open-label Phase 1b clinical trial in adult patients with HeFH, and/or premature coronary artery diseases; VERVE-201, which targets ANGPTL3 and permanently turn off the ANGPTL3 gene in the liver; and VERVE-301, a development candidate that uses a novel in vivo gene editing approach to permanently turn off the LPA gene in the liver to reduce blood Lp(a) levels. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; a license agreement to lipid technology with Novartis Pharma AG; Eli Lilly and Company; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College.
Verve Therapeutics, Inc. Fundamentals Summary
| VERV fundamental statistics | |
|---|---|
| Market cap | US$511.46m |
| Earnings (TTM) | -US$198.71m |
| Revenue (TTM) | US$32.33m |
15.8x
P/S Ratio-2.6x
P/E RatioIs VERV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VERV income statement (TTM) | |
|---|---|
| Revenue | US$32.33m |
| Cost of Revenue | US$22.85m |
| Gross Profit | US$9.48m |
| Other Expenses | US$208.19m |
| Earnings | -US$198.71m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.24 |
| Gross Margin | 29.33% |
| Net Profit Margin | -614.59% |
| Debt/Equity Ratio | 0% |
How did VERV perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/28 06:44 |
| End of Day Share Price | 2025/04/25 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Verve Therapeutics, Inc. is covered by 20 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Konstantinos Biliouris | BMO Capital Markets Equity Research |
| Clarence Powell | BMO Capital Markets Equity Research |
| Whitney Ijem | Canaccord Genuity |